The initial rate of tumour response to vismodegib treatment, can predict a complete response outcome for periocular LA-BCC.

A treatment model was constructed based on the prediction of a CR outcome and the initial response to vismodegib treatment at 3 and 6 months. The study result provide significant new insights can facilitate decision-making on treatment management according to tumour response in patients with POLA BCC.